GSK and CureVac Report Restructuring of their Partnership
Shots:
- GSK & CureVac have restructured their existing partnership (they co-developed mRNA vaccines for seasonal influenza & COVID-19 in P-II and avian influenza in P-I) into a new licensing agreement
- New agreement gives GSK global commercial rights & full development responsibilities of the vaccines. CureVac will get ~$430.4M upfront, ~$1.12B development, regulatory & sales milestones plus high single to low teens tiered royalties, replacing prior financials
- CureVac will keep the exclusive rights of additional undisclosed infectious disease candidates from previous partnership; can develop & collaborate on mRNA vaccines for other diseases, independently. New agreement does not affect its patent litigation against Pfizer/BioNTech
Ref: GSK | Image: GSK
Related News:- CureVac collaborates with GSK to Initiate P-I/II study of Avian Influenza (H5N1)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
